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Abstract
Consumer-directed health plans combine lower premiums with high annual deductibles, Internet-based quality-of-
care information, and health savings mechanisms. These plans may encourage members to seek better value for health 
expenditures but may also decrease essential care. The expansion of high-deductible health plans (HDHPs) represents 
a natural experiment of tremendous proportion. We designed a pre–post, longitudinal, quasi-experimental study to 
determine the effect of HDHPs on diabetes quality of care, outcomes, and disparities. We will use a 13-year rolling 
sample (2001–2013) of members of an HDHP and members of a control group. To reduce selection bias, we will limit 
participants to those whose employers mandate a single health insurance type. The study will measure rates of 
monthly hemoglobin A1c, lipid, and albuminuria testing; availability of blood glucose test strips; and rates of retinal 
examinations, high-severity emergency department visits, and preventable hospitalizations. Results could be used to 
design health plan features that promote high-quality care and better outcomes among people who have diabetes.
Introduction
As discussed by Gregg et al in an accompanying article in this issue of Preventing Chronic Disease (1), diabetes is a 
growing threat to public health. In addition to its detrimental clinical impacts, diabetes creates an economic burden on 
both people and the health care system. Because type 2 diabetes and other chronic diseases are associated with both 
rising costs and modifiable lifestyle factors, consumer-directed health care advocates suggest that health systems 
should encourage greater patient cost-awareness and individual responsibility for health (2,3). They theorize that 
providing patients with information about health care quality while exposing them to full costs will create “activated 
health care consumers” (3). More than a decade ago, managed care organizations began to implement this theoretical 
framework in the form of “consumer-directed health plans” (4). These arrangements typically combine high-deductible 
health plans (HDHPs), Internet-based quality-of-care information, and mechanisms for saving money toward health 
expenses (5). Annual deductibles for the most rapidly growing HDHPs (health savings account–eligible plans [HSAs]) 
range from $2,400 to $12,100 per family (6,7). Advocates theorize that not only will HDHP members seek low-cost, 
high-quality care but they will also be more likely to adopt healthy behaviors to reduce future costs (2,3). For example, 
patients with diabetes may improve their diets, exercise regimens, and adherence to drugs and routine monitoring.
The expansion of HDHPs represents a natural experiment of tremendous proportion. Membership tripled between 
2006 and 2012 (7), and 34% of US workers now have HDHPs (7). The rapid growth in HDHPs has been accompanied 
by concern — based on studies such as the RAND Health Insurance Experiment (8) — that high cost-sharing may 
reduce appropriate as well as inappropriate use. Recent evidence suggests that when necessary care such as essential 
medications (9–11) and screening tests (12,13) are subject to deductibles, use decreases. A newer school of thought has 
promoted “value-based insurance” designs as a remedy (14). These plans seek to broadly control costs using high 
deductibles while preserving evidence-based care through financial incentives. For example, plans may selectively 
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design features (7).
Despite their rapid expansion, the fundamental hypotheses of consumer-directed health plans with value-based 
features have largely been untested. Among diabetic populations, excluding secondary preventive services from cost 
sharing may either preserve use or lead to only small declines (15–18). One study found that both high- and low-
income HDHP members with diabetes experienced small decreases in appropriate diabetes care (17). However, most 
studies have not controlled for member-level selection or examined adverse clinical outcomes. Furthermore, no studies 
have compared the effect of HDHPs with and without full prescription drug cost sharing on diabetes outcomes.
Our investigation seeks to determine the effect of HDHPs on diabetes quality of care, outcomes, and disparities. We 
are using a longitudinal, national data set that includes 2 million members with diabetes. We have 2 primary 
objectives:
To determine the effect of HDHPs on diabetes monitoring and clinical outcomes (including high-severity 
emergency department visits, preventable hospitalizations, and hospitalization days) in a national population and 
among people from vulnerable subgroups (blacks, Hispanics, those of low socioeconomic status, and high-
morbidity patients with diabetes).
1.
To determine the effect of HDHPs with and without full drug cost sharing on rates of medication adherence and 
related clinical outcomes, both overall and among high-risk subgroups.
2.
Study Design
We will identify a 13-year rolling sample (2001–2013) of HDHP members and members of a control group insured by a 
large national health plan. Preliminary analyses indicate that the pool of commercially insured persons from which we 
will select our sample is closely representative of the privately insured US population by age and sex (19). Our 
preliminary data set (2000–2009) includes 1.3 million members aged 18 to 64 years (2.5% aged 18–24, 31.0% aged 25
–39, and 66.5% aged 40–64) with predominantly type 2 diabetes. Most members reside in the South (50.3%) and 
Midwest (28.8%), and 48% are women. Our data source can be linked to member-level sociodemographic variables, 
which provide self-reported information about disposable income, home ownership, and net worth. We will also use 
geocoded variables on socioeconomic status. Data on race/ethnicity, derived from a combination of surname analysis 
and geocoded census data, are provided in the preliminary data set. Approximately 1% have missing data in 2009 for 
education level, income, net worth, and race/ethnicity. Most members with reported race/ethnicity data are white 
(75.0%); 9.8% are black, and 11.5% are Hispanic. Overall, 40.0% of members are in health maintenance organizations 
(HMOs), 18.3% are in preferred-provider organizations (PPOs), and 29.1% are in point-of-service (POS) health plans; 
15.5% were in an account-based HDHP at some point during their enrollment. 
We will use a pre–post, longitudinal, quasi-experimental study design, a rigorous retrospective approach that we have 
used in previous HDHP studies (12,13,18,20). Our eligible cohort will consist of members enrolled in traditional plans 
(HMO, PPO, or POS) with low deductibles ($250 or less individual deductible amount) for at least 1 year who 
experience an employer-mandated switch to an HDHP (ie, employees have no choice in selecting the type of health 
plan coverage). We will follow people for 1 year before and up to 3 years after the date of this mandated transition. Our 
comparison group will comprise contemporaneously enrolled members whose employers chose to remain in 
traditional low-deductible plans during the same period and who also were offered no choice of plan by employers. 
Including only members with mandated insurance coverage reduces the potential for bias resulting from individual 
self-selection into HDHPs. In selecting study groups, we will use employer-level propensity score matching to reduce 
differences between HDHP and traditional employers and member-level propensity score matching to reduce residual 
confounding. Propensity score matching is an established method for selecting a control group with a similar 
likelihood as the intervention group of selecting an intervention (in this case, choosing an HDHP) on the basis of 
observed characteristics when people have not been randomly allocated into study groups (21–23).
Planned Study Outcomes
Our study will focus on the clinical effects of HDHPs. To assess changes in disease monitoring, we will measure rates of 
monthly hemoglobin A1c, lipid, and urine microalbumin testing (but not changes in test results because there is low 
completeness of lab value data); use of blood glucose test strips; and rates of retina examinations. We will graphically 
depict these outcomes using patient-level interrupted time series with comparison series plots. Using segmented 
longitudinal models (18), we will estimate changes in level and trend in use after the date of the switch to HDHPs, 
while controlling for autocorrelation and individual-level covariates using generalized estimating equations (24). Our 
clinical outcomes will include annual rates of high-severity emergency department visits, preventable hospitalizations, 
and inpatient hospital days. We will analyze these less frequent outcomes using a difference-in-differences approach 
with generalized linear models. Difference-in-differences calculations involve subtracting follow-up-minus-baseline 
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intervention is adjusted both for the intervention group’s baseline rates and the control group’s change. This is the 
most rigorous retrospective approach available for estimating changes in low-frequency outcomes when time-series 
plots are unstable. For all analyses, we will stratify the population into vulnerable and less vulnerable groups when 
analyzing the effects of HDHPs on underserved populations, such as people who have low socioeconomic status.
To examine the effect of differential drug cost sharing, we will examine 2 measures of medication availability: the 
average number of oral hypoglycemic or antihypertensive medications available each month and the proportion of 
days that members have lipid-lowering or primary oral hypoglycemic medication available per month (“proportion of 
days covered”) (18). We will use an interrupted time-series design to compare changes in level and trend of medication 
use between the study groups. We will subsequently stratify analyses to determine whether HDHPs that have more 
generous medication coverage are associated with more favorable emergency department and hospital outcomes.
Methodological Decision Making and Limitations
A key design decision by our research team was to restrict the sample to health plan members who have no choice of 
health plan, which has the disadvantage of restricting the study to smaller employers who tend to not offer insurance 
choices. It also precludes the ability to examine different patterns of use between members who self-select HDHPs 
versus those who are required to enroll. However, removing members with a choice of plans has the substantial 
advantage of minimizing self-selection bias, a threat to validity in health insurance studies. We also recognize that 
employers may choose health plans on the basis of the characteristics of their workers, such as anticipated health 
needs or trends in costs; for this reason, we will use propensity score matching to reduce differences between HDHP 
members and traditional plan members and, when possible, use time-series plots and interrupted time-series analyses, 
which will demonstrate whether follow-up trends are different from baseline trends. A limitation of all health 
insurance claims-based studies is that members drop from the sample for reasons such as losing insurance, changing 
jobs, or changing insurer. We will choose only members who were continuously enrolled for a full 2 years. This 
approach removes bias due to differential dropout between groups, but there is also risk that members with longer 
continuous enrollment will have unusual characteristics, limiting generalizability. Preliminary calculations indicate 
that 49% of our sample will have 2 full years of continuous enrollment. Finally, some members in our cohort will be 
eligible to serve as either an HDHP member or a control, if, for example, they had 2 years of traditional plan 
enrollment followed by a year in an HDHP. We are therefore validating a method of randomizing such members to 
either the HDHP or control group.
Implications for Policy Makers and Clinicians
In the context of continuing rapid growth of HDHPs, results from our study can be used to design health plans that 
promote high-quality care and better outcomes among diabetic populations (25). Policy makers could use findings to 
identify tests and therapies that should be exempt from full cost sharing, potentially informing changes to account-
based HDHPs and facilitating extensions of value-based insurance design. Results also may affect the health plan 
arrangements that regulators include in emerging state-based health insurance exchanges. For example, evidence that 
exempting hypoglycemic drugs from full cost sharing preserves appropriate use may make this a standard or mandated 
arrangement.
We will present findings at research and policy conferences attended by policy makers and clinicians. We will also meet 
directly with public and private policy makers at the Centers for Medicare and Medicaid Services, the Centers for 
Disease Control and Prevention (CDC), the Agency for Healthcare Research and Quality, and private insurance 
associations, among others, to discuss the implications of our research for policy decisions.
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